



vTv Therapeutics to Participate in Upcoming Canaccord Genuity and Solebury Trout Conferences

August 6, 2019

HIGH POINT, N.C., Aug. 06, 2019 (GLOBE NEWSWIRE) -- [vTv Therapeutics Inc.](#) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for diabetes and Alzheimer's disease, today announced that it will be participating in the following conferences:

- **Canaccord Genuity's 39th Annual Growth Conference** on August 7-8, 2019 in Boston, MA.

vTv management will present a corporate and clinical overview at 4:30pm ET on Wednesday, August 7, 2019 in the Toronto Room at the InterContinental Hotel in Boston. A live webcast of the presentation can be accessed [here](#) and will be archived for 30 days following the presentation at www.vTvTherapeutics.com.

- **Solebury Trout's 9th Annual Hamptons CEO Roundtable Conference** on Thursday, August 15, 2019 in Bridgehampton, NY.

About vTv Therapeutics

vTv Therapeutics Inc. is a public, clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of diabetes, Alzheimer's disease, and inflammatory disorders.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading "Risk Factors" in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.

Contacts

Investors:

vTv Therapeutics Inc.

IR@vtvtherapeutics.com

or

Media:

Josh Vlasto

212-572-5969

PR@vtvtherapeutics.com



Source: vTv Therapeutics Inc.